BRCA1/2 and other gene mutation carriers with early stage breast cancer are not always receiving cancer treatment as recommended by national guidelines.
Even though more and more people have been tested for hereditary cancer over the years, using this information accurately to guide treatment has not been as successful.
These findings highlight the need for using this information better to help guide appropriate breast cancer treatment, including radiation treatment and chemotherapy.
Check out the full article at https://jamanetwork.com/journals/jamaoncology/fullarticle/2760433.